2′,2′-Difluorodeoxyuridine

2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026) . 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells[1][2][3].

Product Specifications

CAS Number

[114248-23-6]

Product Name Alternative

DFdU; 2',2'-Difluoro-2'-deoxyuridine

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Drug Metabolite

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/2-2-difluorodeoxyuridine.html

Purity

99.87

Solubility

DMSO : 125 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(N1)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=CC1=O

Molecular Formula

C9H10F2N2O5

Molecular Weight

264.18

Precautions

H315, H319, H335

References & Citations

[1]Pauwels B, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol. 2006 Aug;58 (2) :219-28.|[2]Veltkamp SA, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther. 2008 Aug;7 (8) :2415-25.|[3]Veltkamp SA, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos. 2008 Aug;36 (8) :1606-15.